Search for: "Kaisa v. Chang" Results 61 - 74 of 74
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Jun 2020, 3:49 am by Rachel Mumby (Bristows)
Another factor which influences the price spiral is the irreparable changes to the Drug Tariff. [read post]
22 May 2021, 2:07 am by Kluwer Patent blogger
The former strict distinction between originators on the one hand and generic companies on the other hand has clearly changed. [read post]
7 Jan 2019, 6:21 am by Kluwer Patent blogger
Nr 6 of the list, The EPO’s Vision (V) – Trust, was a sad display of what this principle meant to Battistelli: ‘… if trust is supposed to be the EPO’s vision, why does the EPO President apparently believe the EPO needs an “investigative unit” (aka as “Stasi” in examiners’ speech)? [read post]
21 Jan 2019, 4:21 am by Miquel Montañá
This view was rejected by the WTO Dispute Settlement Body in its panel of 17 March 2000 (EC v. [read post]
13 Feb 2024, 1:33 am by Kluwer Patent blogger
If you make a mistake, it is very difficult to go back and it is very difficult to ‘change lanes’. [read post]
In an earlier post I explained the issues that the proposed EU Regulation on SEPs intends to address, and why neither the market nor the courts solve them. [read post]
In the first judicial determination in the world of its type, the Australian Federal Court has held that artificial intelligence systems or devices can be “inventors” for the purpose of the Patents Act 1990 (Cth) (Thaler v Commissioner of Patents [2021] FCA 879). [read post]
5 Dec 2019, 12:59 am by Francois Pochart
It is likely that the part of the draft amendment of the IPC relating to appeals will not change much after the consultation, as it is based on the new texts of the Trademarks Package. [read post]
29 May 2023, 11:43 am by Kluwer Patent blogger
These provisions, placed today in Chapter V of the UPCA, include the definition of the patent’s owner prerogatives to prevent the direct and indirect use of the invention (Art. 25 and 26), the list of limitations concerning the scope of patent protection, including inter alia, acts done privately or for experimental purposes, the use of biological material for the purpose of breeding, discovering and developing other plant varieties (Art. 27), the condition of the right for prior use… [read post]